Reported Late Monday, PAVmed Q1 2024 Adj EPS $(0.99) Beats $(1.67) Estimate, Sales $1.010M Miss $1.053M Estimate
Reported Late Monday, PAVmed Q1 2024 Adj EPS $(0.99) Beats $(1.67) Estimate, Sales $1.010M Miss $1.053M Estimate
週一晚間公佈，PAVMed2024年第一季度經調整後每股收益美元（0.99美元）超過預期（1.67美元），銷售額爲10.1億美元，低於10.53萬美元的預期
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.67) by 40.72 percent. This is a 42.77 percent increase over losses of $(1.73) per share from the same period last year. The company reported quarterly sales of $1.010 million which missed the analyst consensus estimate of $1.053 million by 4.06 percent. This is a 126.46 percent increase over sales of $446.000 thousand the same period last year.
PAVMed（納斯達克股票代碼：PAVM）公佈的季度虧損爲每股0.99美元，比分析師普遍預期的1.67美元（1.67美元）高出40.72個百分點。與去年同期每股虧損1.73美元（1.73）相比，增長了42.77％。該公司公佈的季度銷售額爲10.1億美元，比分析師普遍預期的10.53億美元低4.06％。這比去年同期的44.6萬美元銷售額增長了126.46％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。